1515 sustained improvement in growth velocity (gv) & bone histology (bh) with 250hd3 (250) therapy (rx) in chronic renal failure (crf)
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:

ABSTRACT Linear growth failure is a major complication of CRF unique to children and is related to renal osteodystrophy (ROD). 19 children, ages 2.8-16.4 yrs with CRF and BH of osteomalacia
(OM), osteitis fibrosa (OF) or both (OFM) were given 1-2 mcg/kg/d of 25D to evaluate effects on ROD & GV. GV was defined by standard deviation scores on Tanner growth charts, the
preferred method of expressing growth in pts with CRF. Group GV (mean±SEM) was -1.75±.45 in the pre-Rx year, increasing to +.2±.31 after the 1st Rx yr, and correlated with an increase in
serum 25D of 42±8 ng/ml to 244±20 ng/ml (r=.37, p<.002). Pre-Rx BH showed 7 pts with OM, 9 with OFM, & 3 with OF. Pre-Rx GV was similar in the 3 groups, but increased in OM
(p<.002) while remaining unchanged in OFM (p=NS) after the 1st Rx year. Data were insufficient to analyze OF pts. BH after the 1st Rx year normalized in 4/7 OM, 2/9 OFM, and 2/3 OF. GV
remained unchanged (p=NS) after 1st Rx year over the subsequent 3 Rx yrs in all BH groups despite 7 pts progressing to ESRF. Changes in GV & BH did not correlate with CO2, PO4, Ca, iPTH
or GFR when pre-Rx levels were compared to 1st or later Rx years. In conclusion: 25D often heals abnormal BH, especially OM; is associated with an increase in GV after 1st Rx year and its
preservation in ensuing Rx years. Supported in part by The Upjohn Company. ARTICLE PDF AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Univ. of Pa. Sch. Med. Children's Hosp. of Phila.
& Yale Univ. Sch. Med., New Haven Craig B Langman, Alice T Mazur, Roland Baron & Michael E Norman * Depts. of Ped. Neph. & Med., Craig B Langman, Alice T Mazur, Roland Baron
& Michael E Norman Authors * Craig B Langman View author publications You can also search for this author inPubMed Google Scholar * Alice T Mazur View author publications You can also
search for this author inPubMed Google Scholar * Roland Baron View author publications You can also search for this author inPubMed Google Scholar * Michael E Norman View author publications
You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Langman, C., Mazur, A., Baron, R. _et al._
1515 SUSTAINED IMPROVEMENT IN GROWTH VELOCITY (GV) & BONE HISTOLOGY (BH) WITH 250HD3 (250) THERAPY (RX) IN CHRONIC RENAL FAILURE (CRF). _Pediatr Res_ 15 (Suppl 4), 695 (1981).
https://doi.org/10.1203/00006450-198104001-01538 Download citation * Issue Date: 01 April 1981 * DOI: https://doi.org/10.1203/00006450-198104001-01538 SHARE THIS ARTICLE Anyone you share the
following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer
Nature SharedIt content-sharing initiative